Eric Poma, CEO of Molecular Templates, said: “Cancer therapeutics is a crowded and competitive field. Molecular Templates’s platform technology is compelling because it allows us to rapidly screen for molecular markers that uniquely identify various types of cancer cells, and it allows us to combine into a single therapeutic compound both the specific cancer binding agents and a novel mechanism of action to kill targeted cells.”